LYN-1604 hydrochloride is a potent inhibitor of ULK1, a key kinase in the autophagy pathway essential for cellular homeostasis and survival. It is primarily investigated for its potential in cancer therapy, particularly in targeting tumors by inhibiting autophagy-dependent mechanisms that promote cancer cell proliferation and resistance to treatment. This positions it as a candidate for precision medicine approaches, including combination therapies to enhance efficacy against drug-resistant cancers. Additionally, research explores its applications in neurodegenerative diseases and other disorders involving autophagy dysregulation. Currently, it is in preclinical and early clinical stages to assess safety, efficacy, and potential side effects.